PolyPid Ltd.
PYPDHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframePolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to. The company carries a $109.5M market cap, placing it firmly in the micro-cap category. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
Market Cap
$109.5M
Beta
1.42
P/E (TTM)
—
P/E (Fwd)
-4.39
EPS (TTM)
$-1.31
EPS (Fwd)
$-1.23
ROE
-243.6%
ROA
-74.6%
Cash
$6.6M
Total Debt
$1.6M
Free CF
-$17.4M
52W Change
54.4%
Annual Financials
Cash vs Debt
Where PYPD stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PYPD finished 15.22% above its 150-day moving average ($4.60) and 18.04% above its 200-day moving average ($4.49). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PYPD overbought or oversold?
At the September 3, 2026 close, PYPD's RSI(14) was 74.3, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $6.6M in cash and $1.6M in debt, PYPD maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$17.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -243.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PYPD.